{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:44:56Z","timestamp":1768034696698,"version":"3.49.0"},"reference-count":120,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1053\/j.ajkd.2019.12.016","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T04:01:03Z","timestamp":1586404863000},"page":"665-683","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C"],"prefix":"10.1053","volume":"75","author":[{"given":"David","family":"Roth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy D.","family":"Bloom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miklos Z.","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter P.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deirdre","family":"Sawinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan E.","family":"Sise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norah A.","family":"Terrault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ajkd.2019.12.016_bib1","first-page":"S1","article-title":"KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"109","year":"2008","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"10.1053\/j.ajkd.2019.12.016_bib2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1053\/j.ajkd.2008.08.005","article-title":"KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD","volume":"52","author":"Gordon","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2019.12.016_bib3","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"Afdhal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2019.12.016_bib4","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa1702417","article-title":"Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection","volume":"378","author":"Zeuzem","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2019.12.016_bib5","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-naive and treatment experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2019.12.016_bib6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","article-title":"Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment","volume":"377","author":"Gane","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2019.12.016_bib7","doi-asserted-by":"crossref","first-page":"109","DOI":"10.7326\/M16-1205","article-title":"Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: a randomized trial","volume":"166","author":"Colombo","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2019.12.016_bib8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S2468-1253(17)30116-4","article-title":"Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial","volume":"2","author":"Bruchfeld","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.kisu.2018.06.001","article-title":"KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"8","year":"2018","journal-title":"Kidney Int Suppl"},{"issue":"18","key":"10.1053\/j.ajkd.2019.12.016_bib11","first-page":"362","article-title":"Testing for HCV infection: an update of guidance for clinicians and laboratorians","volume":"62","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1053\/j.ajkd.2019.12.016_bib12","unstructured":"US Preventive Services Task Force. Hepatitis C: screening. 2013. https:\/\/www.uspreventiveservicestaskforce.org\/Page\/Document\/Update Summary Final\/hepatitis-C-screening. Accessed March 10, 2020."},{"key":"10.1053\/j.ajkd.2019.12.016_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2369-14-187","article-title":"Hepatitis C virus itself is a causal risk factor for chronic kidney disease beyond traditional risk factors: a 6-year nationwide cohort study across Taiwan","volume":"14","author":"Chen","year":"2013","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2019.12.016_bib14","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/ki.2013.455","article-title":"A\u00a0nationwide cohort study suggest that hepatitis C virus infection is associated with increased risk of chronic kidney disease","volume":"85","author":"Chen","year":"2014","journal-title":"Kidney Int"},{"issue":"12","key":"10.1053\/j.ajkd.2019.12.016_bib15","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","article-title":"Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systemic review and meta-analysis","volume":"60","author":"Fabrizi","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1053\/j.ajkd.2019.12.016_bib16","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/hep.27664","article-title":"Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans","volume":"61","author":"Molnar","year":"2015","journal-title":"Hepatology"},{"issue":"5","key":"10.1053\/j.ajkd.2019.12.016_bib17","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jhep.2017.12.003","article-title":"Higher risk of renal disease in chronic hepatitis C patients: antiviral therapy survival benefit in patients on hemodialysis","volume":"68","author":"Soderholm","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2215\/CJN.07940716","article-title":"Mortality, hospitalization, and quality of life among patients with hepatitis C infection on hemodialysis","volume":"12","author":"Goodkin","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2019.12.016_bib19","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1525-139X.2002.00051.x","article-title":"National surveillance of dialysis-associated diseases in the United States, 2000","volume":"15","author":"Finelli","year":"2002","journal-title":"Semin Dial"},{"key":"10.1053\/j.ajkd.2019.12.016_bib20","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.ajkd.2010.01.025","article-title":"Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients","volume":"56","author":"Patel","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2019.12.016_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/cid\/cis382","article-title":"Cost-effective screening for acute hepatitis C virus infection in HIV-infected men who have sex with men","volume":"55","author":"Linas","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"RR-5","key":"10.1053\/j.ajkd.2019.12.016_bib22","first-page":"1","article-title":"Recommendations for preventing transmission of infections among chronic hemodialysis patients","volume":"50","year":"2001","journal-title":"MMWF Recomm Rep"},{"key":"10.1053\/j.ajkd.2019.12.016_bib23","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"issue":"4","key":"10.1053\/j.ajkd.2019.12.016_bib24","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10620-007-9966-2","article-title":"A\u00a0cost identification analysis of screening and surveillance of hepatitis C infection in a prospective cohort of dialysis patients","volume":"53","author":"Somsouk","year":"2008","journal-title":"Dig Dis Sci"},{"issue":"4","key":"10.1053\/j.ajkd.2019.12.016_bib26","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/j.ajkd.2012.04.003","article-title":"Association of hepatitis C virus infection with risk of ESRD: a population-based study","volume":"60","author":"Su","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2019.12.016_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0100790","article-title":"Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"issue":"8","key":"10.1053\/j.ajkd.2019.12.016_bib28","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1002\/lt.25059","article-title":"Achieving sustained virological response in liver transplant recipients with hepatitis C decreases risk of decline in renal function","volume":"24","author":"Satapathy","year":"2018","journal-title":"Liver Transpl"},{"issue":"1","key":"10.1053\/j.ajkd.2019.12.016_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.kint.2019.04.030","article-title":"Direct-acting antiviral therapy slows kidney function decline in patients with hepatitis C virus infection and chronic kidney disease","volume":"97","author":"Sise","year":"2020","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2019.12.016_bib30","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2215\/CJN.04320510","article-title":"Transient elastography to assess hepatic fibrosis in hemodialysis chronic hepatitis C patients","volume":"6","author":"Liu","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2019.12.016_bib31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/ki.2010.74","article-title":"The ratio of aminotransferase to platelets is a useful index for predicting hepatic fibrosis in hemodialysis patients with chronic hepatitis C","volume":"78","author":"Liu","year":"2010","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2019.12.016_bib32","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hep.21681","article-title":"Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection","volume":"46","author":"Schiavon","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1053\/j.ajkd.2019.12.016_bib33","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2893.2009.01190.x","article-title":"Prediction of significant liver fibrosis in kidney transplant patients with chronic hepatitis C virus infection: the TX-3 index","volume":"17","author":"Schiavon","year":"2010","journal-title":"J\u00a0Viral Hepat"},{"issue":"6","key":"10.1053\/j.ajkd.2019.12.016_bib34","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/ndt\/gft485","article-title":"Can aminotransferase-to-platelet ratio index and other non-invasive markers effectively reduce liver biopsies for renal transplant evaluation of hepatitis C virus-positive patients?","volume":"29","author":"Jiang","year":"2014","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"10.1053\/j.ajkd.2019.12.016_bib35","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1097\/01.tp.0000183399.85804.02","article-title":"Diagnostic accuracy of the fibrotest in hemodialysis and renal transplant patients with chronic hepatitis C virus","volume":"80","author":"Varaut","year":"2005","journal-title":"Transplantation"},{"issue":"3","key":"10.1053\/j.ajkd.2019.12.016_bib36","doi-asserted-by":"crossref","first-page":"c289","DOI":"10.1159\/000320751","article-title":"Validation of biochemical markers for the prediction of liver fibrosis and necroinflammatory activity in hemodialysis patients with chronic hepatitis C","volume":"117","author":"Canbakan","year":"2011","journal-title":"Nephron Clin Pract"},{"issue":"1","key":"10.1053\/j.ajkd.2019.12.016_bib37","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/hep.28906","article-title":"Portal hypertensive bleeding in cirrhosis: risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases","volume":"65","author":"Garcia-Tsao","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1053\/j.ajkd.2019.12.016_bib38","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1002\/hep.30046","article-title":"Glecaprevir\/pibrentasvir treatment in liver or kidney transplant patients with hepatitis C virus infection","volume":"68","author":"Reau","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1053\/j.ajkd.2019.12.016_bib39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/CEJ.0b013e32834572fa","article-title":"Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden","volume":"20","author":"Hofmann","year":"2011","journal-title":"Eur J Cancer Prev"},{"issue":"12","key":"10.1053\/j.ajkd.2019.12.016_bib40","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/archinte.167.12.1271","article-title":"Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease","volume":"167","author":"Tsui","year":"2007","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1053\/j.ajkd.2019.12.016_bib41","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1053\/j.ajkd.2008.03.009","article-title":"Association of hepatitis C virus infection with prevalence and development of kidney disease","volume":"51","author":"Moe","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2019.12.016_bib42","first-page":"S1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"10.1053\/j.ajkd.2019.12.016_bib43","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12072-011-9284-9","article-title":"Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection","volume":"6","author":"Satapathy","year":"2012","journal-title":"Hepatol Int"},{"issue":"10","key":"10.1053\/j.ajkd.2019.12.016_bib44","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1872-034X.2011.00845.x","article-title":"Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy","volume":"41","author":"Arase","year":"2011","journal-title":"Hepatol Res"},{"issue":"32","key":"10.1053\/j.ajkd.2019.12.016_bib45","doi-asserted-by":"crossref","first-page":"e1334","DOI":"10.1097\/MD.0000000000001334","article-title":"A\u00a0Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease","volume":"94","author":"Chen","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1053\/j.ajkd.2019.12.016_bib46","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/gutjnl-2014-308163","article-title":"Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection","volume":"64","author":"Hsu","year":"2015","journal-title":"Gut"},{"issue":"4","key":"10.1053\/j.ajkd.2019.12.016_bib47","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"issue":"9","key":"10.1053\/j.ajkd.2019.12.016_bib48","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s10096-016-2692-y","article-title":"Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV\/HCV-coinfected patients who achieved sustained virological response","volume":"35","author":"Leone","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"2","key":"10.1053\/j.ajkd.2019.12.016_bib49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/hep.29505","article-title":"Chronic hepatitis C virus (HCV) increases the risk of chronic kidney disease (CKD) while effective HCV treatment decreases the incidence of CKD","volume":"67","author":"Park","year":"2018","journal-title":"Hepatology"},{"issue":"11","key":"10.1053\/j.ajkd.2019.12.016_bib50","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1111\/jvh.13173","article-title":"Prevalence, mortality and healthcare utilization among Medicare beneficiaries with hepatitis C in haemodialysis units","volume":"26","author":"Deshpande","year":"2019","journal-title":"J Viral Hepat."},{"key":"10.1053\/j.ajkd.2019.12.016_bib51","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1016\/j.cgh.2017.04.046","article-title":"Confluence of epidemics of hepatitis C, diabetes, obesity, and chronic kidney disease in the United States population","volume":"15","author":"Lazo","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib52","unstructured":"AASLD\/IDSA. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org. Accessed February 13, 2020."},{"key":"10.1053\/j.ajkd.2019.12.016_bib53","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/cix364","article-title":"Effect of paritaprevir\/ritonavir\/ombitasvir\/dasabuvir and ledipasvir\/sofosbuvir regimens on survival compared with untreated hepatitis C virus-infected persons: results from ERCHIVES","volume":"65","author":"Butt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ajkd.2019.12.016_bib54","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1097\/TP.0000000000000479","article-title":"Shorter waitlist times and improved graft survivals are observed in patients who accept hepatitis C virus+ renal allografts","volume":"99","author":"Scalea","year":"2015","journal-title":"Transplantation"},{"key":"10.1053\/j.ajkd.2019.12.016_bib55","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib56","unstructured":"FDA Drug Safety Communication. FDA warns about rare occurrence of serious liver injury with use of hepatitis C medicines Mavyret, Zepatier, and Vosevi in some patients with advanced liver disease. https:\/\/www.fda.gov\/safety\/medwatch-safety-alerts-human-medical-products\/hepatitis-c-medicines-mavyret-zepatier-and-vosevi-drug-safety-communication-due-rare-occurrence. Accessed February 13, 2020."},{"key":"10.1053\/j.ajkd.2019.12.016_bib57","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/apt.13790","article-title":"Real-world effectiveness and safety of ombitasvir\/paritaprevir\/ritonavir\u00a0+\/- dasabuvir\u00a0+\/- ribavirin in hepatitis C: AMBER study","volume":"44","author":"Flisiak","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1053\/j.ajkd.2019.12.016_bib58","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1053\/j.gastro.2016.02.078","article-title":"Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease","volume":"150","author":"Pockros","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1053\/j.ajkd.2019.12.016_bib59","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1111\/hepr.12851","article-title":"Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment","volume":"47","author":"Suda","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1053\/j.ajkd.2019.12.016_bib60","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor sofosbuvir","volume":"54","author":"Kirby","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1053\/j.ajkd.2019.12.016_bib61","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.jhep.2019.05.028","article-title":"Sofosbuvir\/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis","volume":"71","author":"Borgia","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib62","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena","year":"2016","journal-title":"Liver Int"},{"key":"10.1053\/j.ajkd.2019.12.016_bib64","article-title":"Safety and efficacy of treatment with once-daily ledipasvir\/sofosbuvir (90\/400 mg) for 12 weeks in genotype 1 HCV-infected patients with severe renal impairment","volume":"66","author":"Lawitz","year":"2017","journal-title":"Hepatology"},{"issue":"suppl","key":"10.1053\/j.ajkd.2019.12.016_bib65","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S0618-8278(19)30419-0","article-title":"Ledipasvir\/sofosbuvir for 8, 12, or 24 weeks is safe and effective in patients undergoing dialysis","volume":"70","author":"Chuang","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib63","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12985-019-1140-x","article-title":"Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis","volume":"16","author":"Li","year":"2019","journal-title":"Virol J"},{"key":"10.1053\/j.ajkd.2019.12.016_bib66","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMc1705221","article-title":"Trial of transplantation of HCV-infected kidneys into uninfected recipients","volume":"376","author":"Goldberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1053\/j.ajkd.2019.12.016_bib67","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M17-2871","article-title":"Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to noninfected recipients: an open-label nonrandomized trial","volume":"168","author":"Durand","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2019.12.016_bib68","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7326\/M17-0377","article-title":"Hepatitis B virus reactivation associated with direct-acting antiviral therapy for chronic hepatitis C virus: a review of cases reported to the U.S. Food and Drug Administration adverse event reporting system","volume":"166","author":"Bersoff-Matcha","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1053\/j.ajkd.2019.12.016_bib69","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cgh.2016.06.023","article-title":"Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents","volume":"15","author":"Wang","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib70","doi-asserted-by":"crossref","first-page":"549","DOI":"10.2215\/CJN.06920711","article-title":"Hepatitis C virus infection and kidney disease: a meta-analysis","volume":"7","author":"Fabrizi","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2019.12.016_bib71","doi-asserted-by":"crossref","first-page":"iii314","DOI":"10.1093\/ndt\/gfv183.31","article-title":"Hepatitis C prevalence and clinical outcomes in the Dialysis Outcomes and Practice Patterns Study","volume":"30","author":"Bieber","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2019.12.016_bib72","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1093\/ndt\/gfq696","article-title":"Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey","volume":"26","author":"Saune","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2019.12.016_bib73","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/ndt\/gfh012","article-title":"The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicenter study","volume":"19","author":"Jadoul","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2019.12.016_bib74","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1017\/ice.2015.247","article-title":"A\u00a0large outbreak of hepatitis C virus infections in a hemodialysis clinic","volume":"37","author":"Nguyen","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"suppl 10","key":"10.1053\/j.ajkd.2019.12.016_bib75","first-page":"002","article-title":"Patient-to-patient hepatitis C virus transmissions associated with infection control breaches in a hemodialysis unit","author":"Thompson","year":"2012","journal-title":"J\u00a0Nephrol Ther"},{"key":"10.1053\/j.ajkd.2019.12.016_bib76","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1017\/ice.2015.263","article-title":"Investigation of a case of genotype 5a hepatitis C virus transmission in a French hemodialysis unit using epidemiologic data and deep sequencing","volume":"37","author":"Aho-Glele","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib77","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1086\/605472","article-title":"Hepatitis C virus transmission in hemodialysis units: importance of infection control practices and aseptic technique","volume":"30","author":"Thompson","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib78","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5301\/ijao.5000437","article-title":"Transmission of hepatitis C virus in dialysis units: a systematic review of reports on outbreaks","volume":"38","author":"Fabrizi","year":"2015","journal-title":"Int J Artif Organs"},{"key":"10.1053\/j.ajkd.2019.12.016_bib79","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1111\/ajt.13811","article-title":"CDC urging dialysis providers and facilities to assess and improve infection control practices to stop hepatitis C virus transmission in patients undergoing hemodialysis","volume":"16","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1053\/j.ajkd.2019.12.016_bib80","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000013565","article-title":"Hand contamination with hepatitis C virus in staff looking after hepatitis C-positive hemodialysis patients","volume":"20","author":"Alfurayh","year":"2000","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib81","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jhin.2008.01.026","article-title":"Application of the forensic Luminol for blood in infection control","volume":"68","author":"Bergervoet","year":"2008","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1053\/j.ajkd.2019.12.016_bib82","first-page":"59","article-title":"Hand-borne mechanisms of dissemination of hepatitis C virus in dialysis units: basis for new addenda to the present preventive strategies","volume":"51","author":"Caramelo","year":"1999","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib83","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/S0272-6386(03)00787-X","article-title":"Contamination by hepatitis B and C viruses in the dialysis setting","volume":"42","author":"Froio","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2019.12.016_bib84","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1086\/590564","article-title":"Determinant roles of environmental contamination and noncompliance with standard precautions in the risk of hepatitis C virus transmission in a hemodialysis unit","volume":"47","author":"Girou","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.ajkd.2019.12.016_bib85","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1086\/513727","article-title":"Infectivity of hepatitis C virus in plasma after drying and storing at room temperature","volume":"28","author":"Kamili","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib86","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1053\/j.ajkd.2010.01.025","article-title":"Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients","volume":"56","author":"Patel","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2019.12.016_bib87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2369-5-13","article-title":"The role of hemodialysis machines dedication in reducing hepatitis C transmission in the dialysis setting in Iran: a multicenter prospective interventional study","volume":"5","author":"Shamshirsaz","year":"2004","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib88","first-page":"183","article-title":"Prevention of viral transmission in HD units: the value of isolation","volume":"17","author":"Karkar","year":"2006","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1053\/j.ajkd.2019.12.016_bib89","first-page":"859","article-title":"Patient isolation prevents the transmission of hepatitis C virus infection in hemodialysis units","volume":"31","author":"Harmankaya","year":"2002","journal-title":"Dial Transpl"},{"issue":"suppl 2","key":"10.1053\/j.ajkd.2019.12.016_bib90","first-page":"ii294","article-title":"Decreasing prevalence of hepatitis C virus infection in hemodialysis patients: following KDIGO guidelines","volume":"27","author":"Dzekova-Vidimliski","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2019.12.016_bib91","first-page":"1","article-title":"Recommendations for preventing transmission of infections among chronic hemodialysis patients","volume":"50","author":"Alter","year":"2001","journal-title":"MMWR Recomm Rep"},{"issue":"6","key":"10.1053\/j.ajkd.2019.12.016_bib92","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2018.11.009","article-title":"Mortality and kidney transplantation outcomes among hepatitis C virus\u2013seropositive maintenance dialysis patients: a retrospective cohort study","volume":"73","author":"Sawinski","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1053\/j.ajkd.2019.12.016_bib93","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1046\/j.1523-1755.1998.00883.x","article-title":"Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group","volume":"53","author":"Pereira","year":"1998","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2019.12.016_bib94","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-6143.2004.00652.x","article-title":"Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list","volume":"5","author":"Bloom","year":"2005","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2019.12.016_bib95","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.transproceed.2009.06.103","article-title":"Correlation between fibroscan, liver biopsy, and clinical liver function in patients with hepatitis C virus infection after renal transplantation","volume":"41","author":"Mu\u00f1oz","year":"2009","journal-title":"Transpl Proc"},{"issue":"2","key":"10.1053\/j.ajkd.2019.12.016_bib96","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jhep.2009.11.018","article-title":"Liver stiffness is directly influenced by central venous pressure","volume":"52","author":"Millonig","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1053\/j.ajkd.2019.12.016_bib97","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"4","key":"10.1053\/j.ajkd.2019.12.016_bib98","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMp1505074","article-title":"Transplanting hepatitis C-positive kidneys","volume":"373","author":"Reese","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1053\/j.ajkd.2019.12.016_bib99","doi-asserted-by":"crossref","first-page":"273","DOI":"10.7326\/M18-0749","article-title":"Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial","volume":"169","author":"Reese","year":"2018","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1053\/j.ajkd.2019.12.016_bib100","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1681\/ASN.2019050462","article-title":"National trends in utilization and 1-year outcomes with transplantation of HCV-viremic kidneys","volume":"30","author":"Potluri","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2019.12.016_bib101","doi-asserted-by":"crossref","unstructured":"Molnar MZ, Nair S, Cseprekal O, et\u00a0al. Transplantation of kidneys from hepatitis C-infected donors to hepatitis C-negative recipients: single center experience [published online ahead of\u00a0print 2019]. Am J Transplant. https:\/\/doi.org\/10.1111\/ajt.15530.","DOI":"10.1111\/ajt.15530"},{"issue":"7","key":"10.1053\/j.ajkd.2019.12.016_bib102","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/tri.13410","article-title":"Renal transplantation from seropositive hepatitis C virus donors to seronegative recipients in Spain: a prospective study","volume":"32","author":"Franco","year":"2019","journal-title":"Transpl Int"},{"issue":"17","key":"10.1053\/j.ajkd.2019.12.016_bib103","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa1812406","article-title":"Heart and lung transplants from HCV-infected donors to uninfected recipients","volume":"380","author":"Woolley","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2019.12.016_bib104","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1111\/ajt.15311","article-title":"Transplanting hepatitis C virus-infected hearts into uninfected recipients: a single-arm trial","volume":"19","author":"McLean","year":"2019","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1053\/j.ajkd.2019.12.016_bib105","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.healun.2018.01.1293","article-title":"Early outcomes using hepatitis C-positive donors for cardiac transplantation in the era of effective direct-acting anti-viral therapies","volume":"37","author":"Schlendorf","year":"2018","journal-title":"J\u00a0Heart Lung Transplant"},{"key":"10.1053\/j.ajkd.2019.12.016_bib106","series-title":"Transplantation Ethics","author":"Veatch","year":"2015"},{"key":"10.1053\/j.ajkd.2019.12.016_bib107","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/S0140-6736(14)62484-3","article-title":"Living kidney donation: outcomes, ethics, and uncertainty","volume":"385","author":"Reese","year":"2015","journal-title":"Lancet"},{"key":"10.1053\/j.ajkd.2019.12.016_bib108","doi-asserted-by":"crossref","unstructured":"Kapila N, Al-Khalloufi K, Bejarano PA, Vanatta JM, Zervos XB. Fibrosing cholestatic hepatitis after kidney transplantation from HCV-viremic donors to HCV-negative recipients: a unique complication in the DAA era [published online ahead of print 2019]. Am J Transplant. https:\/\/doi.org\/10.1111\/ajt.15583.","DOI":"10.1111\/ajt.15583"},{"issue":"suppl 8","key":"10.1053\/j.ajkd.2019.12.016_bib109","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndt\/15.suppl_8.28","article-title":"Glomerular disease associated with hepatitis C virus infection in native kidneys","volume":"15","author":"Pouteil-Noble","year":"2000","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2019.12.016_bib110","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ki.1989.84","article-title":"Renal involvement in essential mixed cryoglobulinemia","volume":"35","author":"D'Amico","year":"1989","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2019.12.016_bib111","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.semarthrit.2003.10.001","article-title":"Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients","volume":"33","author":"Ferri","year":"2004","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.ajkd.2019.12.016_bib112","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/039139880703000306","article-title":"Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials","volume":"30","author":"Fabrizi","year":"2007","journal-title":"Int J Artif Organs"},{"issue":"suppl 1","key":"10.1053\/j.ajkd.2019.12.016_bib113","first-page":"S81","article-title":"Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis","volume":"22","author":"Rutledge","year":"2018","journal-title":"Hemodial Int"},{"issue":"11","key":"10.1053\/j.ajkd.2019.12.016_bib114","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1093\/rheumatology\/kew268","article-title":"Persistent mixed cryoglobulinaemia vasculitis despite hepatitis C virus eradication after interferon-free antiviral therapy","volume":"55","author":"Sollima","year":"2016","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1053\/j.ajkd.2019.12.016_bib115","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.gastro.2018.04.024","article-title":"Long-term outcomes of patients with HCV-associated cryoglobulinemic vasculitis after virologic cure","volume":"155","author":"Bonacci","year":"2018","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1053\/j.ajkd.2019.12.016_bib116","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.cgh.2018.05.021","article-title":"Long-term efficacy of interferon-free antiviral treatment regimens in patients with Hepatitis C virus-associated cryoglobulinemia vasculitis","volume":"17","author":"Cacoub","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1053\/j.ajkd.2019.12.016_bib117","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hep.29125","article-title":"Development of proteinuria and focal segmental glomerulosclerosis during direct-acting antiviral therapy for hepatitis C virus infection","volume":"66","author":"Hogan","year":"2017","journal-title":"Hepatology"},{"issue":"3","key":"10.1053\/j.ajkd.2019.12.016_bib118","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ekir.2016.06.006","article-title":"Lupus-like immune complex-mediated glomerulonephritis in patients with hepatitis C virus infection treated with oral, interferon-free, direct-acting antiviral therapy","volume":"1","author":"Sise","year":"2016","journal-title":"Kidney Int Rep"},{"issue":"4","key":"10.1053\/j.ajkd.2019.12.016_bib119","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000493807","article-title":"Incidence and characteristics of de novo renal cryoglobulinemia after direct-acting antivirals treatment in an Egyptian hepatitis C cohort","volume":"140","author":"Fayed","year":"2018","journal-title":"Nephron"},{"issue":"3","key":"10.1053\/j.ajkd.2019.12.016_bib120","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/ckj\/sfy055","article-title":"Mixed cryoglobulinaemia vasculitis after sustained hepatitis C virological response with direct-acting antivirals","volume":"12","author":"Barbieri","year":"2019","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.ajkd.2019.12.016_bib121","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","article-title":"A\u00a0randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis","volume":"64","author":"De Vita","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1053\/j.ajkd.2019.12.016_bib122","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/art.34322","article-title":"A\u00a0randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis","volume":"64","author":"Sneller","year":"2012","journal-title":"Arthritis Rheum"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620305278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638620305278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:27:58Z","timestamp":1759462078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638620305278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":120,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0272638620305278"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.12.016","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2019.12.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}